KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Prepaid Assets (2016 - 2025)

Historic Prepaid Assets for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to $281.9 million.

  • Alnylam Pharmaceuticals' Prepaid Assets rose 14100.75% to $281.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $281.9 million, marking a year-over-year increase of 14100.75%. This contributed to the annual value of $281.9 million for FY2025, which is 14100.75% up from last year.
  • According to the latest figures from Q4 2025, Alnylam Pharmaceuticals' Prepaid Assets is $281.9 million, which was up 14100.75% from $188.0 million recorded in Q3 2025.
  • Alnylam Pharmaceuticals' Prepaid Assets' 5-year high stood at $281.9 million during Q4 2025, with a 5-year trough of $76.0 million in Q1 2021.
  • Over the past 5 years, Alnylam Pharmaceuticals' median Prepaid Assets value was $131.3 million (recorded in 2022), while the average stood at $140.4 million.
  • The largest annual percentage gain for Alnylam Pharmaceuticals' Prepaid Assets in the last 5 years was 14100.75% (2025), contrasted with its biggest fall of 2452.96% (2025).
  • Alnylam Pharmaceuticals' Prepaid Assets (Quarter) stood at $88.1 million in 2021, then surged by 50.91% to $132.9 million in 2022, then fell by 4.92% to $126.4 million in 2023, then dropped by 7.45% to $117.0 million in 2024, then skyrocketed by 141.01% to $281.9 million in 2025.
  • Its last three reported values are $281.9 million in Q4 2025, $188.0 million for Q3 2025, and $147.3 million during Q2 2025.